# Adam Margolin

> Adam Margolin is a computational biologist turned biotech founder who co-founded Flashpoint Therapeutics, a clinical-stage company engineering spherical-nucleic-acid nanomedicines that aim to turn weak cancer therapies into curative ones. After a 20-year academic career that took him from Wharton and Wall Street to running the #3-ranked genetics department in the country at Mount Sinai, and a stint as a Venture Partner at Khosla Ventures, he teamed with Northwestern nanotech pioneer Chad Mirkin to build Flashpoint. He led the company as founding CEO through a $10M seed round before handing the chief executive role to biotech veteran Barry Labinger in 2025. His mission is deeply personal: his mother died of cancer when he was three.

- **Role:** Co-Founder of Flashpoint Therapeutics (founding CEO 2021-2025)
- **Organizations:** Flashpoint Therapeutics, Khosla Ventures, NextVivo, Icahn School of Medicine at Mount Sinai, Oregon Health & Science University, Sage Bionetworks
- **Nationality:** American
- **Education:** Bachelor's degree, Wharton School, University of Pennsylvania, Master's in Computer Science, University of Pennsylvania, PhD, Columbia University
- **Known for:** Co-founded Flashpoint Therapeutics, a clinical-stage structural nanomedicine company, Raised $10M seed financing led by Riyadh-based deep tech firm Beta Lab (Oct 2023), Built Mount Sinai genetics into the #3-ranked genetics department in the country, scaling from ~500 to 700 people and growing revenue by over $20M annually

## Career timeline

- **early career** — Studied at Wharton and worked on Wall Street - 'that's what a kid who likes math does'
- **2000s** — Pivoted to computational biology, applying financial-style analytics to predicting effective cancer drugs
- **academic** — Director of Computational Biology and Professor at Oregon Health & Science University
- **academic** — Director of Computational Biology and co-Leader of Strategy at Sage Bionetworks
- **2018** — Recruited by Mount Sinai to lead a new $200M precision medicine program; named Chair of Genetics and Genomic Sciences, Director of the Icahn Institute for Data Science and Genomic Technology, Senior Associate Dean for Precision Medicine
- **2021** — Joined Khosla Ventures as Venture Partner; led therapeutic platform company creation and served as CEO of NextVivo, a cancer cell therapy company
- **2021-2023** — Co-founded Flashpoint Therapeutics with Chad Mirkin and Michelle Teplensky; became founding CEO
- **2023** — Closed $10M seed financing led by Beta Lab to advance structural nanomedicine pipeline
- **2025** — Transitioned from founding CEO to Co-Founder as Barry Labinger was appointed CEO

## Achievements

- Co-founded Flashpoint Therapeutics, a clinical-stage structural nanomedicine company
- Raised $10M seed financing led by Riyadh-based deep tech firm Beta Lab (Oct 2023)
- Built Mount Sinai genetics into the #3-ranked genetics department in the country, scaling from ~500 to 700 people and growing revenue by over $20M annually
- Internationally recognized computational biology researcher with widely-used methodologies
- Led NextVivo, a cancer cell therapy company, as CEO under Khosla Ventures
- Flashpoint preclinical data: 35x increased co-delivery to immune cells, 80x stronger immune activation, 6.5x greater tumor killing, near-curative or curative efficacy across 9 tumor models

## Latest updates

- **2023-10** — Flashpoint Therapeutics announced $10M seed financing led by Beta Lab to pioneer nanotechnology-enabled medicines, with Margolin as CEO and founder.
- **2025-07** — Flashpoint appointed biotech veteran Barry Labinger as CEO; Margolin transitioned to Co-Founder, with the board crediting him for establishing the foundation of the company.

## Links

- Website: https://flashpoint.bio
- LinkedIn: https://www.linkedin.com/in/adam-margolin-332a196/

---

Profile page: https://yespress.io/adam-margolin
Published by YesPress — https://yespress.io
Last updated: 2026-06-25